The William Blair & Company report outlined some key themes and important trends to watch as we enter 2023 and provided the best stock ideas for the upcoming 12-month period.

• Seagen Inc SGEN Padcev could potentially revolutionize the treatment paradigm of metastatic urothelial carcinoma. The analyst also said that Seagen’s status as a large-cap biopharmaceutical company could provide a means for investors to manage volatility against macro uncertainty.

Related: Merck’s Seagen Acquisition Hits Speed ​​Braker Over Pricing Agreement: Report

• For Neurocrine Biosciences, Inc. NBIX, wrote William Blair that with Ingrezza the company is in the midst of one of the most successful launches of neurology drugs in recent history. Free cash flow helped support a grossly underappreciated pipeline without the need for dilutive financing in this uncertain macro environment.





• The analyst wrote Crystal Biotech Inc KRYS The HSV-1 platform and its low-risk use in dermatological conditions made it an attractive take-out candidate. Its Jeune subsidiary was considered differentiated technology in the field of aesthetic indications.





• Chinook Therapeutics Inc KDNY has performed well in 2022 and the continued flow of clinical updates on internal programs could give the stock a boost. The company was well funded and took short-term capital risk off the table in the macro environment. William Blair said Chinook is well positioned in the rapidly evolving landscape.





• For UniQure NV QUREsaid William Blair, two main drivers – Hemgenix (hemophilia B gene therapy) and additional clinical data from the Phase 1/2 trial of AMT130 in Huntington’s disease — could give the stock significant upside potential in 2023.





• Albireo Pharma Inc ALBO was William Blair’s first choice and said Bylvay’s sales should continue to grow into 2023 as launch in the product’s first indication, PFIC, gained momentum during approval Alagille Syndrome in the USA and Europe expected in 2023,…